MEDI8897

Phase 3Small molecule

AstraZeneca

MEDI8897 is one of 35 small molecule programs targeting Respiratory tract infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

Respiratory Tract InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

80 competitors in Respiratory Tract Infection

#DrugCompanyPhaseTrials

Advil

KKenvue Brands

Approved

1 2

Merrem

BB. Braun Medical Inc.

Approved

—3

Tobrex

VViatris Specialty LLC

Approved

—4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

1 6

Veklury

Gilead

Phase 2

1 7

Quietus

Merck & Co.

Phase 2

1 8

Rapivab

BBioCryst Pharmaceuticals

Phase 3

1 9

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 10

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus2 trials

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Completed· AstraZeneca logo

AstraZeneca·Phase 2/3·NCT03959488·925 enrolled

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02290340·151 enrolled

Respiratory tract infection1 trial

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03979313·3,012 enrolled

Safety and Efficacy1 trial

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02878330·1,453 enrolled

Phase 11 trial

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02114268·342 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MEDI8897. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEDI8897 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEDI8897. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

MEDI8897

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Syncytial Virus2 trials

Respiratory tract infection1 trial

Safety and Efficacy1 trial

Phase 11 trial

References

Drug Info

Quick Facts

Related News